209 related articles for article (PubMed ID: 36946421)
1. Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors.
Lu W; Fan M; Ji W; Tse J; You I; Ficarro SB; Tavares I; Che J; Kim AY; Zhu X; Boghossian A; Rees MG; Ronan MM; Roth JA; Hinshaw SM; Nabet B; Corsello SM; Kwiatkowski N; Marto JA; Zhang T; Gray NS
J Med Chem; 2023 Apr; 66(7):4617-4632. PubMed ID: 36946421
[TBL] [Abstract][Full Text] [Related]
2. Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling.
Fan M; Lu W; Che J; Kwiatkowski NP; Gao Y; Seo HS; Ficarro SB; Gokhale PC; Liu Y; Geffken EA; Lakhani J; Song K; Kuljanin M; Ji W; Jiang J; He Z; Tse J; Boghossian AS; Rees MG; Ronan MM; Roth JA; Mancias JD; Marto JA; Dhe-Paganon S; Zhang T; Gray NS
Elife; 2022 Oct; 11():. PubMed ID: 36300789
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of TEAD transcription factors in cancer.
Pobbati AV; Kumar R; Rubin BP; Hong W
Trends Biochem Sci; 2023 May; 48(5):450-462. PubMed ID: 36709077
[TBL] [Abstract][Full Text] [Related]
5. Discovering inhibitors of TEAD palmitate binding pocket through virtual screening and molecular dynamics simulation.
Li Y; Li Y; Ning C; Yue J; Zhang C; He X; Wang Y; Liu Z
Comput Biol Chem; 2022 Jun; 98():107648. PubMed ID: 35288361
[TBL] [Abstract][Full Text] [Related]
6. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
[TBL] [Abstract][Full Text] [Related]
7. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
[TBL] [Abstract][Full Text] [Related]
8. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present).
Zagiel B; Melnyk P; Cotelle P
Expert Opin Ther Pat; 2022 Aug; 32(8):899-912. PubMed ID: 35768160
[TBL] [Abstract][Full Text] [Related]
9. Toward the Design of Ligands Selective for the C-Terminal Domain of TEADs.
Liberelle M; Toulotte F; Renault N; Gelin M; Allemand F; Melnyk P; Guichou JF; Cotelle P
J Med Chem; 2022 Apr; 65(8):5926-5940. PubMed ID: 35389210
[TBL] [Abstract][Full Text] [Related]
10. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.
Hori N; Okada K; Takakura Y; Takano H; Yamaguchi N; Yamaguchi N
J Biol Chem; 2020 Jun; 295(26):8798-8807. PubMed ID: 32385107
[TBL] [Abstract][Full Text] [Related]
11. Small-Molecule Cyanamide Pan-TEAD·YAP1 Covalent Antagonists.
Bum-Erdene K; Yeh IJ; Gonzalez-Gutierrez G; Ghozayel MK; Pollok K; Meroueh SO
J Med Chem; 2023 Jan; 66(1):266-284. PubMed ID: 36562717
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode.
Hu L; Sun Y; Liu S; Erb H; Singh A; Mao J; Luo X; Wu X
Elife; 2022 Nov; 11():. PubMed ID: 36398861
[TBL] [Abstract][Full Text] [Related]
13. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
14. Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3.
Lu T; Li Y; Lu W; Spitters T; Fang X; Wang J; Cai S; Gao J; Zhou Y; Duan Z; Xiong H; Liu L; Li Q; Jiang H; Chen K; Zhou H; Lin H; Feng H; Zhou B; Antos CL; Luo C
Acta Pharm Sin B; 2021 Oct; 11(10):3206-3219. PubMed ID: 34729310
[TBL] [Abstract][Full Text] [Related]
15. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
Hagenbeek TJ; Zbieg JR; Hafner M; Mroue R; Lacap JA; Sodir NM; Noland CL; Afghani S; Kishore A; Bhat KP; Yao X; Schmidt S; Clausen S; Steffek M; Lee W; Beroza P; Martin S; Lin E; Fong R; Di Lello P; Kubala MH; Yang MN; Lau JT; Chan E; Arrazate A; An L; Levy E; Lorenzo MN; Lee HJ; Pham TH; Modrusan Z; Zang R; Chen YC; Kabza M; Ahmed M; Li J; Chang MT; Maddalo D; Evangelista M; Ye X; Crawford JJ; Dey A
Nat Cancer; 2023 Jun; 4(6):812-828. PubMed ID: 37277530
[TBL] [Abstract][Full Text] [Related]
16. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
[TBL] [Abstract][Full Text] [Related]
17. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
[TBL] [Abstract][Full Text] [Related]
18. Leveraging the Fragment Molecular Orbital and MM-GBSA Methods in Virtual Screening for the Discovery of Novel Non-Covalent Inhibitors Targeting the TEAD Lipid Binding Pocket.
Kim J; Jin H; Kim J; Cho SY; Moon S; Wang J; Mao J; No KT
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791396
[TBL] [Abstract][Full Text] [Related]
19. Novel Allosteric Effectors Targeting Human Transcription Factor TEAD.
Ibrahim MT; Verkhivker GM; Misra J; Tao P
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240355
[TBL] [Abstract][Full Text] [Related]
20. Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling.
Noland CL; Gierke S; Schnier PD; Murray J; Sandoval WN; Sagolla M; Dey A; Hannoush RN; Fairbrother WJ; Cunningham CN
Structure; 2016 Jan; 24(1):179-186. PubMed ID: 26724994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]